Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375495 | 0.84 | MEN1 (0.44) | ALDH1A1L3MBTL1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4239389 | 0.82 | FABP4 (0.48) | PRMT5L3MBTL1LMNAPOLBHTT | |
| SCHEMBL15402594 | 0.81 | FABP4 (0.43) | GAAALDH1A1L3MBTL1LMNAHTT | |
| SCHEMBL15402835 | 0.81 | MAPT (0.44) | GAAALDH1A1L3MBTL1LMNANPSR1 | |
| SCHEMBL27778530 | 0.81 | L3MBTL1 (0.36) | GAAALDH1A1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL15402444 | 0.80 | FABP4 (0.43) | ALDH1A1L3MBTL1POLBSMN1; SMN2MEN1 | |
| SCHEMBL15401423 | 0.80 | LMNA (0.43) | ALDH1A1L3MBTL1LMNASMN1; SMN2MEN1 | |
| SCHEMBL15402252 | 0.80 | ALDH1A1 (0.47) | ALDH1A1POLBHTTNPSR1MEN1 | |
| SCHEMBL15401828 | 0.80 | MEN1 (0.46) | GAAALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15403550 | 0.80 | FABP4 (0.43) | FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101849000-B | Reductase, gene thereof and method of using the same | SUMITOMO CO LTD | 2013-07-03 | — | — | CN | claimed |
| CN-101679967-B | Reductase, gene thereof, and method for using same | SUMITOMO CHEMICAL CO | 2013-06-12 | — | — | CN | claimed |
| CN-101849000-B | Reductase, gene thereof and method of using the same | SUMITOMO CO LTD | 2013-07-03 | — | — | CN | disclosed |
| CN-101679967-B | Reductase, gene thereof, and method for using same | SUMITOMO CHEMICAL CO | 2013-06-12 | — | — | CN | disclosed |
| US-8252563-B2 | Reductase, gene thereof and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8192967-B2 | Reductase, gene thereof and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-06-05 | — | — | US | disclosed |
| CN-101983243-A | Process for producing optically active ortho-substituted mandelic acid compound | SUMITOMO CHEMICAL CO | 2011-03-02 | — | — | CN | disclosed |
| US-20110033905-A1 | PROCESS FOR PRODUCING OPTICALLY-ACTIVE ORTHO-SUBSTITUTED MANDELIC ACID COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2241629-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ORTHO-SUBSTITUTED MANDELIC ACID COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| CN-101849000-A | Reductase, gene thereof and method of using the same | SUMITOMO CHEMICAL CO | 2010-09-29 | — | — | CN | disclosed |
| US-20100221799-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100112701-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| CN-101679967-A | Reductase, gene thereof, and method for using same | SUMITOMO CHEMICAL CO | 2010-03-24 | — | — | CN | disclosed |
| EP-2138578-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
| EP-2138579-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112701-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | BLVRB, ADH7, DHCR7 | PRMT5 739/4885GAA 1688/4885ALDH1A1 277/4885 |
| US-20100221799-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | BLVRB, DHCR7, GRHPR | PRMT5 579/4885GAA 1276/4885ALDH1A1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.